PMGC HOLDINGS INC. Selling and Marketing Expense
PMGC HOLDINGS INC. (ELAB) reported Selling and Marketing Expense of $721.49 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2024-08-14
- PMGC HOLDINGS INC. selling and marketing expense for the quarter ending 2024-06-30 was $721.49K, a 532.60% increase year-over-year.
- PMGC HOLDINGS INC. selling and marketing expense for the quarter ending 2024-03-31 was $393.04K, a 282.79% increase year-over-year.
- PMGC HOLDINGS INC. selling and marketing expense for the quarter ending 2023-12-31 was -$315.78M.
- PMGC HOLDINGS INC. selling and marketing expense for the quarter ending 2023-09-30 was $99.71M, a 36.08% increase year-over-year.
- PMGC HOLDINGS INC. selling and marketing expense for fiscal 2023 was $660.29K, a 242.36% increase from fiscal 2022.
- PMGC HOLDINGS INC. selling and marketing expense for fiscal 2022 was $192.86K.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $721.49K 10-Q · filed 2024-08-14 | $1.11M 10-Q · filed 2024-08-14 | -$314.66M derived: sum of 3 quarters · filed 2024-08-14 | -$214.95M derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | $393.04K 10-Q · filed 2024-05-15 | -$315.38M derived: sum of 2 quarters · filed 2024-05-15 | -$215.67M derived: sum of 3 quarters · filed 2024-05-15 | -$215.56M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-12-31 | -$315.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$216.07M derived: sum of 2 quarters · filed 2024-03-29 | -$215.95M derived: sum of 3 quarters · filed 2024-08-14 | $660.29K 10-K · filed 2024-03-29 |
| 2023-09-30 | $99.71M 10-Q · filed 2023-12-11 | $99.82M derived: sum of 2 quarters · filed 2024-08-14 | $316.44M 10-Q · filed 2023-12-11 | -$34.64M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-06-30 | $114.05K 10-Q · filed 2024-08-14 | $216.73K 10-Q · filed 2024-08-14 | -$134.35M derived: sum of 3 quarters · filed 2024-08-14 | -$61.08M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $102.68K 10-Q · filed 2024-05-15 | -$134.47M derived: sum of 2 quarters · filed 2024-05-15 | -$61.19M derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$134.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$61.30M derived: sum of 2 quarters · filed 2024-03-29 | $192.86K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $73.27M 10-Q · filed 2023-12-11 | $134.76M 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B |